This study is looking at the long-term safety and how well APG777 works for people with moderate-to-severe atopic dermatitis (a chronic skin condition causing itchy rashes). You would be eligible if you have already completed a previous study with APG777 and your doctor believes you would benefit from continuing treatment. The study will give APG777 as an injection under the skin, either every 12 or 24 weeks. Researchers will be tracking any side effects you experience for up to three years to understand the long-term safety of APG777. The study aims to enroll about 350 participants.

Study design

This is a long-term extension study, meaning it follows participants from a previous APG777 study. It is a double-blind study, so neither you nor your doctor will know which treatment schedule you are on. Approximately 350 participants are planned.

What's involved

You would have a screening visit that aligns with your last visit in a previous APG777 study, followed by an extended treatment period and a post-treatment follow-up period. You will also use the same non-prescription moisturizer you used in the prior study.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for treatment-emergent adverse events (side effects) for up to 3 years after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.